+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07408232

Study to Assess Safety, Tolerability, and Effects of Oral OCT-980 in Adults With Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa

Led by Octant, Inc. · Updated on 2026-09-24

18

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating OCT-980, an oral small molecule designed to treat rhodopsin-associated autosomal dominant retinitis pigmentosa RHO-adRP, a progressive retinal disease causing vision loss with no approved therapy. This integrated Phase 12 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of OCT-980 in both healthy volunteers and participants diagnosed with RHO-adRP. The study includes a completed Phase 1a in healthy volunteers and a current Phase 1b2 dose escalation study in RHO-adRP patients. Participants with RHO-adRP receive OCT-980 tablets orally once daily at doses that increase in a stepwise manner over the study. The Phase 1b2 portion is open-label, multi-center, and lasts up to 48 weeks, focusing on multiple ascending doses to evaluate how the drug behaves in the body and its effects. This phase follows the initial safety evaluation done in healthy volunteers during Phase 1a. Participants undergo genetic testing confirmation and regular assessments including visual acuity tests and blood sampling for drug levels and safety labs. Researchers monitor safety and tolerability from baseline up to 60 weeks, including pharmacokinetic and pharmacodynamic evaluations. The study duration allows close observation of participants while collecting data on the drugs potential effects over nearly a year.

CONDITIONS

Brief Title

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Research Team

O

Octant adRP Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here